BMP2K and myelodysplastic syndrome: Moreover; Gleason et al., (2014) reported that CD16XCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33 targets and reverse immune suppression of NK cells and induced myeloid suppressor cells target cell lysis.